Status:
UNKNOWN
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
Lead Sponsor:
Bicetre Hospital
Conditions:
Rare Diseases
X-linked Hypophosphatemia
Eligibility:
All Genders
1-20 years
Phase:
PHASE4
Brief Summary
In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for \<13- and \>13-years old children affected with X-linked hypophosphatemia. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- insufficient response or refractory to conventional therapy;
- complications of conventional therapy: hypercalciuria and/or nephrocalcinosis, and/or persistent secondary hyperparathyroidism;
- need for rapid restoration of phosphate metabolism, e.g., late diagnosis (aged \>8 years) and/or preparation for planned orthopaedic surgery.
Exclusion
Key Trial Info
Start Date :
March 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 16 2022
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04419363
Start Date
March 18 2018
End Date
September 16 2022
Last Update
June 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Bicetre
Le Kremlin-Bicêtre, France, 94270